Prudential Financial Inc. raised its stake in Kindred Biosciences Inc (NASDAQ:KIN) by 18.9% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 52,920 shares of the biopharmaceutical company’s stock after purchasing an additional 8,410 shares during the quarter. Prudential Financial Inc. owned approximately 0.19% of Kindred Biosciences worth $415,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of the business. Virtu KCG Holdings LLC grew its stake in Kindred Biosciences by 41.7% in the second quarter. Virtu KCG Holdings LLC now owns 15,285 shares of the biopharmaceutical company’s stock valued at $131,000 after purchasing an additional 4,495 shares in the last quarter. Goldman Sachs Group Inc. boosted its stake in shares of Kindred Biosciences by 28.5% during the 1st quarter. Goldman Sachs Group Inc. now owns 22,336 shares of the biopharmaceutical company’s stock worth $157,000 after acquiring an additional 4,954 shares during the period. Nationwide Fund Advisors bought a new position in shares of Kindred Biosciences during the 2nd quarter worth approximately $100,000. JPMorgan Chase & Co. bought a new position in shares of Kindred Biosciences during the 2nd quarter worth approximately $119,000. Finally, Trexquant Investment LP bought a new position in shares of Kindred Biosciences during the 2nd quarter worth approximately $120,000. Hedge funds and other institutional investors own 66.85% of the company’s stock.

Several brokerages have recently commented on KIN. HC Wainwright set a $10.00 target price on Kindred Biosciences and gave the stock a “buy” rating in a research note on Tuesday, December 5th. B. Riley set a $11.00 target price on Kindred Biosciences and gave the stock a “buy” rating in a research note on Tuesday, December 5th. ValuEngine upgraded Kindred Biosciences from a “sell” rating to a “hold” rating in a research note on Friday, December 1st. Finally, Zacks Investment Research downgraded Kindred Biosciences from a “buy” rating to a “hold” rating in a research note on Wednesday, October 11th. Three analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $9.63.

Kindred Biosciences Inc (KIN) opened at $7.70 on Monday. Kindred Biosciences Inc has a one year low of $4.10 and a one year high of $9.65.

Kindred Biosciences (NASDAQ:KIN) last released its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.33) by $0.04. research analysts anticipate that Kindred Biosciences Inc will post -1.19 EPS for the current year.

COPYRIGHT VIOLATION WARNING: This article was first posted by Watch List News and is owned by of Watch List News. If you are accessing this article on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright laws. The correct version of this article can be viewed at https://www.watchlistnews.com/prudential-financial-inc-has-415000-holdings-in-kindred-biosciences-inc-kin/1756929.html.

Kindred Biosciences Profile

Kindred Biosciences, Inc is a development-stage biopharmaceutical company. The Company is focused on developing therapies for pets. The Company’s product pipeline consists of small molecules and biologics for a range of indications in dogs, cats and horses. The Company is developing product candidates for over 20 indications and focused on small molecule products and canine and feline biologics products.

Institutional Ownership by Quarter for Kindred Biosciences (NASDAQ:KIN)

Receive News & Ratings for Kindred Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kindred Biosciences Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.